| Full text | |
| Author(s): |
Braga, Marina Souza
[1, 2]
;
Turaca, Thiago Lauro
[3]
;
Foguer, Karen
[1, 2]
;
Barbosa Chaves, Karen Cristina
[1, 2]
;
Pesquero, Joao Bosco
[3]
;
Chammas, Roger
[4]
;
Schor, Nestor
[1]
;
Bellini, Maria Helena
[1, 2]
Total Authors: 8
|
| Affiliation: | [1] Univ Fed Sao Paulo, Div Nephrol, Sao Paulo - Brazil
[2] IPEN CNEN, Dept Biotechnol, Sao Paulo - Brazil
[3] Univ Fed Sao Paulo, Dept Biophys, Sao Paulo - Brazil
[4] Univ Sao Paulo, Dept Radiol, Sao Paulo - Brazil
Total Affiliations: 4
|
| Document type: | Journal article |
| Source: | BIOMEDICINE & PHARMACOTHERAPY; v. 67, n. 6, p. 511-515, JUL 2013. |
| Web of Science Citations: | 5 |
| Abstract | |
Renal cell carcinoma (RCC) is characterized by high vascular endothelial growth factor (VEGF) production and, consequently, excessive angiogenesis. Several strategies have been developed to target angiogenesis as a method for treating metastatic RCC (mRCC). Endostatin (ES) is a C-terminal fragment of collagen XVIII that has antiangiogenic activity. The aim of this study was to investigate the predictive value of circulating VEGF-A in a murine model of mRCC after ES gene therapy. ES therapy did not affect the levels of collagen XVIII/ES or ES in the tissue. The circulating level of ES was increased in the control and ES-treated groups (normal vs. control, P < 0.05 and ES-treated vs. control, P < 0.001), and the intratumoral vessels were significantly decreased (ES-treated vs. control, P < 0.05). ES therapy decreased the VEGF mRNA levels. The tissue and circulating levels of VEGF in the control group were significantly higher than normal (P < 0.01 and P < 0.05, respectively). Treatment with ES significantly reduced the VEGF concentrations in both compartments (P < 0.001 for tissue and P < 0.05 for plasma). Our findings indicate that in addition to the directly targeted tumor vessels, ES exerts its antitumor effect by down-regulating VEGF gene expression in renal tumor cells. Additionally, our findings point to the predictive value of VEGF for ES therapy. (C) 2013 Elsevier Masson SAS. All rights reserved. (AU) | |
| FAPESP's process: | 10/18969-0 - NF-kB regulation in the renal cell carcinoma after endostatin gene therapy |
| Grantee: | Maria Helena Bellini Marumo |
| Support Opportunities: | Regular Research Grants |